SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Arthur H)
 

Sökning: WFRF:(Arthur H) > (2015-2019) > Telotristat Ethyl, ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004804naa a2200493 4500
001oai:DiVA.org:uu-315064
003SwePub
008170301s2017 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3150642 URI
0247 a https://doi.org/10.1200/JCO.2016.69.27802 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Kulke, Matthew H.u Dana Farber Canc Inst, Boston, MA 02115 USA.4 aut
2451 0a Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome
264 1c 2017
338 a print2 rdacarrier
520 a Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This placebo-controlled phase III study evaluated telotristat ethyl in this setting. Patients and Methods Patients (N = 135) experiencing four or more BMs per day despite stable-dose somatostatin analog therapy received (1: 1: 1) placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg three times per day orally during a 12-week double-blind treatment period. The primary end point was change from baseline in BM frequency. In an open-label extension, 115 patients subsequently received telotristat ethyl 500 mg. Results Estimated differences in BM frequency per day versus placebo averaged over 12 weeks were -0.81 for telotristat ethyl 250 mg (P < .001) and -0.69 for telotristat ethyl 500 mg (P,.001). At week 12, mean BM frequency reductions per day for placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg were -0.9, -1.7, and -2.1, respectively. Responses, predefined as a BM frequency reduction >= 30% from baseline for >= 50% of the double-blind treatment period, were observed in 20%, 44%, and 42% of patients given placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg, respectively. Both telotristat ethyl dosages significantly reduced mean urinary 5-hydroxyindole acetic acid versus placebo at week 12 (P < .001). Mild nausea and asymptomatic increases in gamma-glutamyl transferase were observed in some patients receiving telotristat ethyl. Follow-up of patients during the open-label extension revealed no new safety signals and suggested sustained BM responses to treatment. Conclusion Among patients with carcinoid syndrome not adequately controlled by somatostatin analogs, treatment with telotristat ethyl was generally safe and well tolerated and resulted in significant reductions in BM frequency and urinary 5-hydroxyindole acetic acid.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Hoersch, Dieteru Zentralklinik Bad Berka, Bad Berka, Germany.4 aut
7001 a Caplin, Martyn E.u Royal Free Hosp, London, England.4 aut
7001 a Anthony, Lowell B.u Univ Kentucky, Lexington, KY USA.4 aut
7001 a Bergsland, Emilyu Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.4 aut
7001 a Öberg, Kjellu Uppsala universitet,Endokrin tumörbiologi4 aut0 (Swepub:uu)kjellob
7001 a Welin, Staffanu Uppsala universitet,Institutionen för medicinska vetenskaper4 aut0 (Swepub:uu)stafweli
7001 a Warner, Richard R. P.u Icahn Sch Med Mt Sinai, New York, NY 10029 USA.4 aut
7001 a Lombard-Bohas, Catherineu Hosp Civils Lyon, Hop Edouard Herriot, Lyon, France.4 aut
7001 a Kunz, Pamela L.u Stanford Univ, Palo Alto, CA 94304 USA.4 aut
7001 a Grande, Enriqueu Hosp Univ Ramon y Cajal, Madrid, Spain.4 aut
7001 a Valle, Juan W.u Univ Manchester, Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England.4 aut
7001 a Fleming, Douglasu Ipsen Biosci, Cambridge, MA USA.4 aut
7001 a Lapuerta, Pablou Lexicon Pharmaceut, The Woodlands, TX USA.4 aut
7001 a Banks, Phillipu Lexicon Pharmaceut, The Woodlands, TX USA.4 aut
7001 a Jackson, Shannau Lexicon Pharmaceut, The Woodlands, TX USA.4 aut
7001 a Zambrowicz, Brianu Lexicon Pharmaceut, The Woodlands, TX USA.4 aut
7001 a Sands, Arthur T.u Lexicon Pharmaceut, The Woodlands, TX USA.4 aut
7001 a Pavel, Marianneu Charite, Berlin, Germany.4 aut
7102 a Dana Farber Canc Inst, Boston, MA 02115 USA.b Zentralklinik Bad Berka, Bad Berka, Germany.4 org
7730 t Journal of Clinical Oncologyg 35:1, s. 14-23q 35:1<14-23x 0732-183Xx 1527-7755
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-315064
8564 8u https://doi.org/10.1200/JCO.2016.69.2780

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy